The company is rapidly filling the void left by competitors in the subscription pain management device market. It is hiring sales representatives left, right and center, but it is still maintaining profitability and cash generation. The hiring will stop towards the end of the year, allowing profitability to seriously ramp next year. Despite some hopefully […]
Zynex Is A Winner
May 5th, 2020 · Comments Off on Zynex Is A Winner
Tags: ZYXI
Zynex Breaks Out With The Flywheel Effect Yet To Come
October 9th, 2019 · Comments Off on Zynex Breaks Out With The Flywheel Effect Yet To Come
The company basks in device orders growing at 30% sequentially and 95% y/y. Revenue will follow more slowly, but ultimately much more pronounced as the company gets 80% of revenue from supplies, not device sales, producing a flywheel effect. Enjoying 80%+ gross margin, profits, positive cash flow and no debt, it’s not too late to […]
Tags: ZYXI
Bull Thesis In Zynex Confirmed By Q2 Figures
August 5th, 2019 · Comments Off on Bull Thesis In Zynex Confirmed By Q2 Figures
The company produced stellar Q2 figures despite a rather epic sales force ramp that took S&M 111% higher in the quarter. The company can easily afford this sales ramp, and we don’t think investors appreciate the inherent flywheel effect that will come as a result. We are also getting a little more optimistic about the […]
Tags: ZYXI
The Zynex Party Has Much Further To Go
June 10th, 2019 · Comments Off on The Zynex Party Has Much Further To Go
The medical device company sprouts SaaS-like metrics; 30%+ growth, 80% recurring revenues, 80%+ gross margin and it’s profitable and cash flow positive. The big sales force expansion depress these figures now, but will create a tremendous ratcheting up effect later. There are multiple expansion opportunities like overseas and other devices. Source: The Zynex Party Has […]
Tags: ZYXI